Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
68.9M
-
Shares change
-
+960K
-
Total reported value, excl. options
-
$1.6B
-
Value change
-
+$23.5M
-
Number of buys
-
65
-
Number of sells
-
-31
-
Price
-
$23.22
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q1 2019
118 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q1 2019.
Denali Therapeutics Inc. - Common Stock (DNLI) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.9M shares
of 145M outstanding shares and own 47.4% of the company stock.
Largest 10 shareholders include Crestline Management, LP (19.5M shares), Flagship Pioneering Inc. (8.01M shares), VANGUARD GROUP INC (6.58M shares), BAILLIE GIFFORD & CO (6.26M shares), FMR LLC (5.49M shares), BlackRock Inc. (4.55M shares), Temasek Holdings (Private) Ltd (4.41M shares), STATE STREET CORP (1.67M shares), LORD, ABBETT & CO. LLC (1.66M shares), and FIL Ltd (1.27M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.